Physician profile

Mark Faruque

Family Medicine · Taylorsville, NC

NPI 1386764173

$329.56

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$31.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $94.58 2019-2023 Wegovy, Saxenda
Amarin Pharma, INC. $53.31 2020-2021
Takeda Pharmaceuticals U.S.A., INC. $45.36 2020-2021
Daiichi Sankyo INC. $40.37 2021
Sunovion Pharmaceuticals INC. $38.26 2019-2020
Glaxosmithkline, LLC. $29.71 2019
Bayer Healthcare Pharmaceuticals INC. $15.57 2024
Lilly USA, LLC $12.40 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark Faruque

$329.56

in general payments reported 2019-2025

Years
2019-2024
Top company
Novo Nordisk INC

https://glasscript.com/doctor/107693/mark-faruque

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.